4 news items
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
ADAP
GLPG
30 May 24
Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
GLPG
4 Apr 24
of the studies is to assess the Objective Response Rate (ORR) and the secondary objectives include the analysis of the Complete Response (CR), duration
- Prev
- 1
- Next